Human Lymph Node-Derived Fibroblastic and Double-Negative Reticular Cells Alter Their Chemokines and Cytokines Expression Profile Following Inflammatory Stimuli

Patricia Severino1, Diana Torres Palomino1,2, Heliene Alvarenga1,2, Camila Bononi Almeida1, Denise Cunha Pasqualim3, Adriano Cury3,4, Paolo Rogério Salvalaggio1,3, Antonio Luiz De Vasconcelos Macedo3, Maria Claudina Andrade1, Thiago Aloia1, Silvio Bromberg3, Luiz Vicente Rizzo1, Fernanda Agostini Rocha1 and Luciana C. Marti1*

1Albert Einstein Research and Education Institute, Hospital Israelita Albert Einstein, São Paulo, Brazil, 2Programa de Alergia e Imunopatologia, Faculdade de Medicina da Universidade de São Paulo (FMUSP), São Paulo, Brazil, 3Hospital Israelita Albert Einstein, São Paulo, Brazil, 4Endocrinology Department, Santa Casa de Misericórdia de Sao Paulo, São Paulo, Brazil

Lymph node (LN) is a secondary lymphoid organ with highly organized and compartmentalized structure. LNs harbor B, T, and other cells among fibroblastic reticular cells (FRCs). FRCs are characterized by both podoplanin (PDPM/gp38) expression and by the lack of CD31 expression. FRCs are involved in several immune response processes but mechanisms underlying their function are still under investigation. Double-negative cells (DNCs), another cell population within LNs, are even less understood. They do not express PDPM or CD31, their localization within the LN is unknown, and their phenotype and function remain to be elucidated. This study evaluates the gene expression and cytokines and chemokines profile of human LN-derived FRCs and DNCs during homeostasis and following inflammatory stimuli. Cytokines and chemokines secreted by human FRCs and DNCs partially diverged from those identified in murine models that used similar stimulation. Cytokine and chemokine secretion and their receptors expression levels differed between stimulated DNCs and FRCs, with FRCs expressing a broader range of chemokines. Additionally, dendritic cells demonstrated increased migration toward FRCs, possibly due to chemokine-induced chemotaxis since migration was significantly decreased upon neutralization of secreted CCL2 and CCL20. Our study contributes to the understanding of the biology and functions of FRCs and DNCs and, accordingly, of the mechanisms involving them in immune cells activation and migration.

Keywords: human lymph nodes, fibroblastic reticular cell, double-negative cells, podoplanin, chemokines
INTRODUCTION

The immunological function of lymph nodes (LNs) includes the initiation of antigen-specific immune responses as well as the induction of tolerance when required. These secondary lymphoid organs possess a structured morphology and harbor a variety of cell populations, including lymphocytes B, T, and other less characterized cell populations. Among these, the fibroblastic reticular cells (FRCs) are phenotypically characterized by both podoplanin expression (PDPN, gp38) and by the absence of CD31 expression (1–3). FRCs are known to participate in several immune response processes, including immune cells homing and activation, but essential mechanisms fundamental to these functions are still under investigation (2, 4). The double-negative cells (DNCs) constitute a poorly understood cell population within LNs. These cells do not express gp38 or CD31, their localization within LNs is unclear, and their function remains to be elucidated (5–7).

Fibroblastic reticular cells and DNCs share stromal cells phenotype and are known to secrete chemokines (8). They are involved in the control of migratory patterns and positioning of immune cells during homeostasis or inflammatory response (8). In animal models, FRCs and DNCs react to inflammatory stimuli such as interleukin 1 (IL-1), interferon (IFN)-α, -β, and -γ, and tumor necrosis factor (TNF)-α, by altering chemokines gene and protein expression profiles (9–12). Chemokines constitute a large family of small cytokines involved in immune cells chemotaxis. Some chemokines are considered pro-inflammatory and released upon infection, while others are considered homeostatic and involved in the control of cell migration during tissue development or maintenance. The physiologic importance of this family of mediators results from their specificity because its members induce recruitment of well-defined leukocyte subsets (13, 14).

Chemokines are secreted by FRCs within LNs where they orchestrate the encounter between diverse immune cell types. In murine LNs, FRCs are localized in the paracortex and they produce CCL19 and CCL21, attracting T and dendritic cells via CCR7 (5). IL-7 secretion is also attributed to FRCs (2). IL-7 contributes to the maintenance of naïve T cells survival and IL-7 signaling is regulated by IL-7Rα, a specific receptor, in FRCs (2, 15). Other studies in murine models and humans reported FRCs also producing IL-6 and IL-15 (5, 8, 16).

Our study evaluates the expression of interleukins and chemokines in human-derived FRCs and DNCs under standard culture conditions and following inflammatory stimuli using IFN-γ and TNF-α + IL-1β treatment. IFN-γ induces lymphocytes differentiation and is produced by several immune cell subtypes in response to inflammatory stimulation (17). In contrast, the cytokine TNF-α is secreted by T and B cells in response to antigenic stimulation (18), while IL-1β takes part in several immunologic processes, including T cells differentiation into Th1 and Th2 (10).

We demonstrate that, following inflammatory stimulation, the secretion of interleukins and chemokines by human LN-derived FRCs and DNCs partially differed from those identified in murine models. In addition, FRCs showed a broader range of chemokines being upregulated when compared with DNCs. These results suggest that distinct immune cells subsets may interact with either FRCs or DNCs. Accordingly, dendritic cells demonstrated an increased migration potential toward FRCs following treatment with TNF-α and IL-1β and their migration was significantly decreased upon neutralization of secreted CCL2 or CCL12. These results imply functional differences between FRCs and DNCs within LNs.

MATERIALS AND METHODS

Human LNs

Peripheral or mesenteric human LNs were obtained from four individuals with different ages and clinical status (larynx cancer—LN03, diverticulitis—LN12, breast cancer—LN15 patients, and an organ donor for liver transplantation—LN16) submitted to surgical procedures. All research participants signed an informed consent (approved by Hospital Israelita Albert Einstein research ethics committee under CAAE number: 07768712.4.0000.0071). All LNs were submitted to histopathological examination, which confirmed that they were not visually affected by the disease.

Histopathology and Immunohistochemistry

Formalin-fixed paraffin-embedded LN samples were sectioned into 3 μm thick slices and transferred to microscope slides. The slides containing the tissue were stained with hematoxylin–eosin (HE). Immunohistochemical staining was performed using Autostainer DAKO automated immunohistochemistry slide processing platform according to the manufacturer’s instructions and individual staining was performed for CD20 (clone: L26), CD3 (Polyclonal), and CD68 (clone: PGM-1) antibodies, all from Dako (Glostrup, Denmark). Histopathology and immunohistochemistry were performed by the Clinical Pathology Laboratory from Hospital Israelita Albert Einstein.

Enzymatic Digestion of LNs

For the isolation of the stromal cells, the LN was shredded with a scalpel. Lymphocytes released in the media were collected and frozen for further analysis and the remaining of the lymphoid tissue was washed with Hank’s balanced salt solution (HBSS, Gibco, Carlsbad, CA, USA) and incubated at 37°C for 30 min in 9 mL of HBSS, 1 mL of Accutase (Innovative Cell Technologies, San Diego, CA, USA), 0.6 ng/mL of collagenase type II, and 1 μL of turbo DNase (Invitrogen, Carlsbad, CA, USA). The tube containing the tissue underwent mechanical stirring every 5 min during the 30-min incubation period. After incubation, the LN fragments were vigorously stirred with a needle to complete the tissue disruption. Samples were then centrifuged (500 g, 5 min, 22°C), and the pelleted cells were suspended in DMEM-LG and cultured (5% CO2, 37°C) in 25 cm2 culture flasks. After the third passage, the plastic adherent cells were phenotypically characterized and sorted in two cell populations, FRCs and DNCs, according to the procedures described in the following section.

FRCs and DNCs Immunophenotyping and Sorting by Flow Cytometry

Immunophenotyping of cells was performed with the following antibodies: CD34-PE (clone: 8G12) from BD Biosciences, San
Jose, CA, USA; CD14-Alexa 700 (clone: M5E2), CD29-APC (clone: MAR04), CD35-FTTC (clone: E11), CD44-PerCP-Cy5.5 (clone: G44-26), CD73-PE (clone: AD2), CD90-PE-Cy7 (clone: 5E10), HLA-DR-APC-H7 (clone: G46-6), CD106-FTTC (clone: 51-10C9) all from BD Pharmingen, San Diego, CA, USA; CD31-V450 (clone: WM59), CD45-V500 (clone: H130), CD105-PE-CF546 (clone: 266) all from BD Horizon, San Jose, CA, USA, and gp38/PDPN-APC (polyclonal) from R&D Systems, Minneapolis, MN, USA, and fluorescence minus one (FMO) was used as a fluorescence background control. Briefly, 1 × 10^6 cells were incubated in the dark/room temperature for 30 min in the presence of antibodies at concentrations recommended by the manufacturers. Cells were then washed with buffered solution and at least 10,000 events were acquired using FACS LSRII FORTESSA (BD Biosciences). Cell populations were characterized according to the following reference markers: FRCs: gp38+, CD31−; DNCs: gp38−, CD31−; lymphatic endothelial cells: gp38+, CD31+; blood endothelial cells: gp38−, CD31+ and/or CD106+; follicular dendritic cells (FDCs): gp38+, CD35+; hematopoietic cells: CD45+, CD14+ or CD44+, CD31−; stromal cells markers: CD29, CD44, CD73, CD90, and CD105. Data were analyzed using the FACSDIVA (BD Biosciences) and/or the FlowJo software (Tree Star, Ashland, OR, USA).

After characterization, cells were sorted according to gp38/PDPN expression: gp38/PDPN positive, the FRCs, and gp38/PDPN negative, the DNCs, using FACSAria II cell sorting (BD Biosciences). Cell sorting was performed in order to achieve high cell population purity (>95%). After cell sorting and expansion in culture, an additional step of gp38/PDPN expression verification was performed before every experiment; if purity was below 95% cells were resorted, as described in Figure S1 in Supplementary Material.

**Differentiation of Cells Into Adipocyte-, Chondrocyte-, and Osteocyte-Like Cells**

In order to evaluate FRCs and DNCs stromal cell characteristics, we studied their differentiation potential. Both cell subtypes were cultured in specific differentiation media for 21 days following literature guidelines (19, 20). For adipogenic differentiation, the medium used was Alpha-MEM (Gibco) supplemented with 10% FBS (Gibco), 1 µM dexamethasone, 100 µg/ml 3-isobutyl-1-methylxanthine IBMX, 10 µg/ml insulin, and 100 µM indomethacin (all from Sigma, St. Louis, MO, USA). The osteogenic differentiation medium used was Alpha-MEM supplemented with 10% FBS, 1 µM dexamethasone, 2 µg/ml ascorbic acid, and 10 µM β-glycerophosphate (all from Sigma St. Louis, MO, USA). For chondrogenic lineage differentiation, we used the medium Alpha-MEM supplemented with 10% FBS, 1 µM dexamethasone, 2 µg/ml ascorbic acid and 6.25 µg/ml insulin from Sigma, and 10 ng/ml TGF-β from R&D Systems. After 21 days, cells were fixed and stained with specific dyes to confirm differentiation: the adipogenic cultures were fixed in 4% paraformaldehyde and stained with oil red (Sigma) to indicate the lipid droplets formation inside the cells; cells in osteogenic culture were fixed in 50% ethanol at 4°C and stained with Alizarin Red (Sigma), and the chondrogenic cultures were fixed in crescent ethanol concentrations (70, 90, and 100%) and stained with toluidine blue (Sigma) to identify the proteoglycan-rich matrix.

**Dendritic Cells Differentiation and Maturation**

Monocytes were derived from peripheral blood obtained from four healthy volunteers after they signed an informed consent. Peripheral blood cells were diluted 1:3 with phosphate-buffered saline. The suspension was transferred to a 15-ml conical tube containing 5 ml of Ficoll-Paque 1.077 density (GE Healthcare, UK) and centrifuged (30 min/500 g) at 22°C. The cells from the interface were collected, resuspended, and centrifuged again (5 min/500 g). Cells were then separated according to CD14 expression using a magnetic selection column (Miltenyi Biotec, Bergisch Gladbach, Germany). The CD14 cell population was dispensed into six-well plates containing X-vivo 15 medium (Cambrex) supplemented with antibiotic-antimycotic solution (Gibco). To generate immature dendritic cells (iDCs), the cells were cultured in the presence of human recombinant IL-4 (20 ng/ml) and GM-CSF (50 ng/ml) (both from R&D Systems, Minneapolis, MN, USA) for 6 days (20). Mature DCs were obtained after idC stimulation with LPS 100 ng/ml for 24 h (Sigma-Aldrich). Monocytes and monocyte-derived immature and mature DCs were analyzed for chemokines receptor as described in the following section.

**Lymphocytes Isolation**

Lymphocytes were isolated from peripheral blood obtained from 11 healthy volunteers after they signed an informed consent. An aliquot of whole blood cells was immediately stained for lymphocyte-specific markers and chemokines receptors as described in the following section. Lymphocytes were also isolated from the LNs as described in the Section “Enzymatic Digestion of LNs.” LN-derived lymphocytes (n = 6) were also stained for lymphocyte-specific markers and chemokines receptors as described in the following section. The chemokine receptors expression of the peripheral blood lymphocytes and the LN-derived lymphocytes were compared.

**Dendritic Cells and Lymphocytes Chemokine Receptors Detection by Flow Cytometry**

Immunophenotyping of lymphocytes, monocytes, and monocyte-derived DCs was performed with the following antibodies: CD3-PerCP-Cy5.5 (clone: SK7), CD33-APC (clone: P67.6), and HLA-DR-PerCP-Cy5.5 (clone: G46.6), from BD Biosciences, CD209-FTTC (clone: DCN46), CD8-APC-Cy7 (clone: SK1), CD80-PE (clone: L307.4), CD86-PE (clone: 2331-FUN-1), CCR7-FTTC (clone: 3D12), CD14-PerCP-Cy5.5 (clone: M5E2), CD4-Alexa-700 (clone: RPA-T4), CCR4-PE (clone: 12G5), CCR2-Alexa-647 (clone: 48607), CCR6-PE-Cy7 (clone: 11A9) from BD Pharmingen, CCR3-BV421 (clone: 5E8), CCR5-PE-CF546 (clone: 2D7/CCR5) from BD Horizon. FMO was
used as a fluorescence background control. Briefly, \(1 \times 10^5\) cells were incubated in the dark/room temperature for 30 min in the presence of antibodies at concentrations recommended by the manufacturers. We used FACS Lysing solution (BD Biosciences) for red cells lysing after staining of whole blood. Cells were then washed with buffered solution and at least 10,000 events were acquired using FACS LSRII FORTESSA (BD Biosciences).

Data were analyzed using the FACSDIVA (BD Biosciences) and/or the FlowJo software (Tree Star, Ashland, OR, USA). The gating strategy is described in Figure S2 in Supplementary Material.

**ELISA**

The FRCs and DNCs were cultured with or without inflammatory stimuli provided by either TNF\(\alpha\) (25 ng/mL) in combination with IL-1\(\beta\) (5 ng/mL) treatment or IFN-\(\gamma\) (50 ng/mL) treatment (21, 22). The culture supernatant was removed 24 h after treatment and frozen for ELISA assays. The cells that remained attached to the culture plate were harvested for RNA extraction (see RNA Extraction). We used ELISA Duo set (R&D Systems) for quantification of CCL2, CCL19, and CCL20, Quantikine (R&D Systems) for IL7 and CXCL12 quantification. For IL-6, IL-8, and IL-10, we used reagents from Immunotools (Immunotools, Germany). All procedures followed the manufacturers’ instructions. Plate readings were carried out using the microplate reader SpectraMax® i3 (Molecular Devices, Sunnyvale, CA, USA). Readings were performed at 450/540 nm and the standard curve was set at 4 parameters logistic or log/log curve fit, according to each manufacturer’s protocol.

**Migration Assay**

The FRCs and DNCs were cultured with or without inflammatory stimuli provided by either IFN-\(\gamma\) (50 ng/mL) or TNF-\(\alpha\) (25 ng/mL) in combination with IL-1\(\beta\) (5 ng/mL) treatments. Monocyte-derived iDCs were stained with 5 \(\mu\)M of carboxyfluorescein succinimidyl-ester (CFSE-Invitrogen) for detection using green fluorescence, as previously described (23). The iDCs (2 \(\times\) 10\(^4\) cells) were placed in 3.0 \(\mu\)m transwell inserts (Anopore membranes, Nunc Kamstrup, Denmark) within chambers in 24-well plates containing FRCs or DNCs previously treated for 24 h with inflammatory signals, or in plates with untreated FRCs and DNCs. After 24 h in culture, the insert was removed from the culture plate and cells resting in the upper part of the insert (lose cells) were removed. The filter was removed from the chambers and the fluorescent cells trapped in the transwell were counted using a fluorescence microscope (Olympus IX51).

Aiming to evaluate the impact of CCL2 and CCL20 on dendritic cells migration, iDCs (2 \(\times\) 10\(^3\) cells) were placed on 8.0 \(\mu\)m transwell inserts within chambers (Translucent Membranes, Greiner Bio-One, Vienna, Austria) in 24-well plates containing either FRCs or DNCs previously treated or untreated for 24 h with inflammatory signals. Cells were treated with neutralizing antibodies for CCL2 (2 \(\mu\)g/mL) or CCL20 (5 \(\mu\)g/mL) (ELISA capture antibodies, R&D Systems). After 24 h, the insert was removed from the culture plate and the cells that transmigrated toward FRCs or DNCs were visualized in the lower part of the chamber and counted using the detection of green fluorescence by a fluorescence microscopy (Olympus IX51).

**RNA Extraction**

RNA extraction was carried out using RNAeasy Kit (Qiagen, Valencia, CA, USA) according to the manufacturer’s instructions. For RNA quantification and quality analysis, we used the NanoVue spectrophotometer (GE Healthcare Life Sciences, Little Chalfont, UK).

**Gene Expression Analysis Using DNA Microarrays**

To understand patterns of cytokine and chemokine gene expression by FRCs and DNCs, we used DNA microarrays. We compared FRCs and DNCs that were treated or not with IFN-\(\gamma\) (50 ng/mL) or TNF-\(\alpha\) (25 ng/mL) in combination with IL-1\(\beta\) (5 ng/mL). Cells from four LNs were used for this assay: two LNs isolated from cancer patients (LN04 and LN15), one from a diverticulitis patient (LN12), and one isolated from a healthy liver donor (LN16). Gene expression levels were evaluated using the DNA microarray SurePrint G3 Human Gene Expression 8 × 60K v2 Microarray Kit (Agilent Technologies, USA). Labeling of probes with cyanine 3 dye (Cy3), hybridization, and washing procedures strictly followed the manufacturer’s protocol (One Color Quick Amp Labeling Kit, Agilent Technologies). The arrays were scanned using a SureScan Microarray Scanner (Agilent Technologies, USA) using default parameters for Agilent microarrays. Initial data processing was performed using the Agilent Feature Extraction software (version 10.5), and GeneSpring (Agilent Technologies, USA) was used for data normalization (quantile normalization) and transformation. For the differential gene expression analysis, the gene-level normalized intensities were compared between sample pairs and a fold-change was calculated for each cell type per LN (treated vs untreated cells). The expression data are deposited at the Gene Expression Omnibus site (accession number GSE89612 associated with platform GPL16699).

**Statistical Analysis**

The statistical analysis was performed using the GraphPad Prism program (version 6.02). The Student’s \(t\)-test was used for comparison between two groups or ANOVA for multiple comparisons with Bonferroni correction, when necessary. A minimum \(p < 0.05\) significance was considered for all experiments.

**RESULTS**

**Pathological Analysis of LNs Evidentiate Tissue Integrity**

The pathological analysis showed tissue integrity and absence of metastasis in the cancer-derived LNs. LNs were also evaluated for cells distribution using histochemistry markers for CD3, CD20, and CD68 (24) and, accordingly, we observed that T lymphocytes were present in the paracortex region, B lymphocytes were within the follicles, and the macrophages were distributed throughout the LN. We observed that follicles in cancer-derived LNs were not
as well delimited as those obtained from the healthy liver donor or from the diverticulitis patient (Figures S3A–C in Supplementary Material).

**Cell Subpopulations Isolated from LNs Were Classified as Stromal Cells**

Cells isolated from the human LNs and used in this study were uniform in size and granularity (FSC vs SSC). They did not express markers for endothelial cells (CD31 and CD106), and the absence of CD35 expression indicated the absence of FDCs among them (Figures 1A,B). These cells also did not express hematopoietic markers such as CD14, CD34, CD45, or HLA-DR, they expressed CD29, CD44, CD73, CD90, and CD105 (Figure 1C) and were classified into FRCs and DNCs subpopulations according to PDPN/gp38 expression (Figures 1D–F). They displayed fibroblastic shape and were plastic adherent (Figures 2A–O). FRCs and DNCs were able to differentiate into osteocyte-, chondrocyte-, and adipocyte-like cells (Figures 3A–F). Thus, we concluded that, as expected, the human FRCs and DNCs displayed stromal cells characteristics that fulfill the international phenotypic criteria determined by International Society for Cellular Therapy (19).

**FIGURE 1** | Phenotypic profile and cell sorting of stromal cells isolated from human lymph nodes (LNs). Stromal cells isolated from human LNs (four samples) were analyzed by flow cytometry for: (A) size vs granularity and fluorescence minus one (FMO) for gp38 (FMO vs CD31), histograms of gated cells show unlabeled cells (black line) and stained cells (red line), (B) LN stromal cells were phenotyped in fibroblastic reticular cells (FRCs) or double-negative cells (DNCs) by gp38 and blood endothelial cells, lymphatic endothelial cells, and follicular dendritic cells were excluded due to absence of CD31, CD35, CD106, and HLA-DR expression, (C) FRCs and DNCs showed positivity for CD29, CD44, CD73, CD90, and CD105 and no expression of CD14, CD34, CD45, indicating absence of hematopoietic cells, (D) flow cytometry data showing purity over 97% in the cell sorting of (E) FRCs and (F) DNCs. All four LNs were fully characterized; this figure displays the results from LN12.
Cytokine and Chemokine Expression Was Induced by Inflammatory Factors

Microarray gene expression analysis was used to evaluate the expression of interleukins and chemokines and respective receptors directly involved in immune cells activation and migration following inflammatory stimuli. We hypothesized that DNCs and FRCs are cell subpopulations that may respond differently to such conditions. We compared results from standard culture conditions and cells submitted to 24 h treatment with either IFN-γ or TNF-α + IL-β. A summary of the results is displayed in Table 1, and complete data reports are displayed in Tables S1–S4 in Supplementary Material.

After IFN-γ treatment, we observed upregulation of chemokine genes expression in both FRCs and DNCs, but with marked differences (Table 1). CCL5 and CXCL2 were more expressed in DNCs than in FRCs, while CCL2, CCL8, CCL13, CXCL3,
CXCL8, CXCL9, CXCL10, and CXCL11 were more expressed in FRCs (Table 1). Alterations in the expression levels were also observed after TNF-α + IL-1β treatment, with chemokines being more expressed in treated FRCs when compared to DNCs, and a group of chemokines upregulated only in treated FRCs (CCL3L3, CXCL2, and CXCL11).

To confirm that the differential patterns of chemokines and interleukins expression following treatment was dependent upon the cell type, CCL2, CCL20, CXCL8, and CXCL12 protein levels were evaluated in the culture medium using ELISA. TNF-α + IL-1β stimulation of FRCs and DNCs significantly enhanced CCL2 secretion (26,050 ± 12,608 and 12,677 ± 2,178 pg/mL, respectively) when compared to the correspondent IFN-γ treatment (3,668 ± 524 and 2,390 ± 1,262 pg/mL) or correspondent untreated cells (913 ± 280 and 587 ± 141 pg/mL), corroborating the gene expression results (Figure 4A). Similarly, CCL20...
secretion in FRCs culture was also significantly enhanced after TNFα + IL-1β stimulation (610 ± 176 pg/mL) when compared to IFN-γ (13 ± 2 pg/mL) or untreated cells (14 ± 3 pg/mL) (Figure 4B). There was a moderate secretion of CXCL12 in untreated DNCs (44 ± 33 pg/mL) and in FRCs (67 ± 81 pg/mL), which was not altered by inflammatory stimulation (Figure 4C), while CCL19 was undetectable in every condition.

IL-6 secretion was significantly enhanced in DNCs after TNFα + IL-1β stimulation (54.8 ± 15.2 pg/mL) when compared to IFN-γ (10.7 ± 1.2 pg/mL) and untreated cells (7.6 ± 0.9 pg/mL) (Figure 4D), but there were no significant differences in IL-6 secretion by FRCs (Figure 4D). However, we observed a variation in the expression levels of IL-6 among FRC samples and a relatively high secretion of IL-6 by untreated FRCs (18.21 ± 13 pg/mL) or IFN-γ stimulated FRCs (21.42 ± 12 pg/mL).

Enhanced IL-7 secretion by FRCs was observed after TNFα + IL-1β stimulation (5.7 ± 1.0 pg/mL) when compared to untreated cells (2.7 ± 0.7 pg/mL), but no differences were observed in DNCs (Figure 4E).

CXCL8 (IL-8) secretion was significantly enhanced in FRCs and DNCs after TNFα + IL-1β stimuli (78.4 ± 2.6 and 73.5 ± 2.5 pg/mL, respectively) compared to their respective untreated controls (10.2 ± 4.9 and 4.4 ± 0.4 pg/mL), while IFN-γ did not alter this secretion significantly (Figure 4F). IL-10 secretion by FRCs or DNCs was almost undetectable under standard and inflammatory conditions (Figure 4G).

Our results suggest that the chemokine and cytokine expression of these subpopulations in the LN microenvironment may be important to guarantee homeostasis, which is modified under inflammatory conditions, possibly leading to specific responses.

Chemokine Receptors Expressed by Monocytes, Dendritic Cells, and Lymphocytes Suggest Differential Interaction between FRCs, DNCs, and Immune Cells

Fibroblastic reticular cells and DNCs presented different expression levels of cytokines and chemokines upon inflammatory stimulation. In order to verify whether these expression patterns could lead to a differential interaction with immune cell populations, we evaluated the expression of chemokine receptors in lymphocytes, monocytes, and monocyte-derived DCs. CCR2 was highly expressed in monocytes and DCs, both immature and mature. There were variations in CCR6 and CXCR4 expression and increased expression of CCR3, CCR5, and CCR7 according to the maturation status of the DCs (Figures 5A–F). Regarding lymphocytes, we observed that there were subpopulations expressing all the chemokine receptors evaluated in this study. In addition to those receptors, lymphocytes isolated from LNs expressed higher CXCR4 levels compared to peripheral blood
samples (Figures 6A–C). The chemokine receptors analyzed suggest that the interaction between FRCs and DNCs and immune cells may differ. For instance, we observed an intense upregulation of CCL2 and CCL20 genes and secretion by FRC when compared to DNCs and their respective receptors, CCR2 and CCR6, are expressed in iDCs.

**Monocyte-Derived Dendritic Cells Migrate toward TNF-α + IL-1β-Treated FRCs**

The effect of inflammatory stimulation of FRCs and DNCs on immune cell migration was evaluated by a migration assay using iDCs. We used monocyte-derived DCs and not LN isolated cells, due to the limited number of conventional DCs within LNs and/or circulating in peripheral blood (25). We found a more intense migration of iDCs toward TNF-α + IL-1β-treated FRCs, less migration toward similarly treated DNCs, and lower migration rates toward the untreated cells (Figures 7A–F). iDCs migration toward IFN-γ-treated FRCs or DNCs was low and similar to the controls (Figure 7G).

Since iDCs expressed CCR2 and CCR6 receptors and migrated toward TNF-α + IL-1β-treated FRCs that expressed and secreted high levels of CCL2 and CCL20, we used neutralizing antibodies for these chemokines to confirm their involvement

### TABLE 1 | Gene expression of chemokines and interleukins in double-negative cells (DNCs) and fibroblastic reticular cells (FRCs) following treatment with IFN-γ or TNF-α + IL-1β.

| GENE         | Chemokines and interleukins induced by IFN-γ | Chemokines and interleukins induced by TNF-α + IL-1β |
|--------------|----------------------------------------------|---------------------------------------------------|
| CCL2         | 12.65                                        | 26.74                                             |
| CCL3         | –                                            | 58.92                                             |
| CCL5         | 15.93                                        | 99.25                                             |
| CCL7         | 30.26                                        | 38.53                                             |
| CCL8         | 109.60                                       | 43.45                                             |
| CCL11        | –                                            | –                                                 |
| CCL13        | 72.59                                        | 7.83                                              |
| CCL20        | –                                            | 259.11                                            |
| CXCL1        | –                                            | 667.98                                            |
| CXCL2        | 51.94                                        | 465.36                                            |
| CXCL3        | –                                            | 1,015.14                                          |
| CXCL5        | –                                            | 38.23                                             |
| CXCL6        | –                                            | 779.07                                            |
| CXCL8        | –                                            | 2,141.93                                          |
| CXCL9        | –                                            | –                                                 |
| CXCL10       | 191.19                                       | 122.44                                            |
| CXCL11       | 174.2                                        | –                                                 |
| CCL3L3       | –                                            | 10.01                                             |
| IL-1α        | –                                            | 127.54                                            |
| IL-1β        | –                                            | 579.39                                            |
| IL-41        | 8.07                                         | 19.61                                             |
| IL-6         | –                                            | 26.28                                             |
| IL-11        | –                                            | 352.47                                            |
| IL-15        | –                                            | 29.85                                             |
| IL-32        | 13.23                                        | 10.34                                             |
| IL-33        | 6.26                                         | 22.45                                             |
| IL-36γ       | –                                            | 11.87                                             |
| IL-18 binding protein | – | 168.29 |
| IL-1FN       | –                                            | 14.71                                             |
| IL-3RA       | 7.20                                         | –                                                 |
| IL-7R        | –                                            | 159.50                                            |
| IL15RA       | 6.67                                         | 3.49                                              |

Results represent the average fold-change between treated cells vs controls in four lymph node (LNs) and absent results indicate that uniform upregulation (fold-change > 2.0) was not observed in all four LNs. The DNCs and FRCs used in this experiment were derived from LN04, LN12, LN15, and LN16. Individual data of each LN was included in Tables S1–S4 in Supplementary Material.
FIGURE 4 | Chemokine secretion by fibroblastic reticular cells (FRCs) and double-negative cells in homeostasis and under inflammatory stimuli.

Lymph node stromal cells (derived from LN04, LN12, LN15, and LN16) cultured during 7 days and treated with TNF-α + IL-1β (light gray bar) or IFN-γ (dark gray bar) for 24 h. White bars correspond to cells cultured without treatment. Chemokines and cytokines were measured in each cells supernatant and results presented are the average and standard deviation, (A) CCL2, (B) CCL-20, (C) CXCL-12, (D) IL-6, (E) FRCs IL-7 [IL-7 assay range for cell culture supernatant should be between 0.2 and 10 pg/mL (sensitivity level is 0.1 pg/mL)], (F) IL-8/CXCL-8, (G) IL-10 secretion was lower than 0.1 pg/mL and was not altered by cytokines stimulation (*p < 0.05, ***p < 0.001).

in iDCs migration (Figures 7H–I). Our results showed that iDCs migration toward TNF-α + IL-1β stimulated FRCs or DNCs treated independently with anti-CCL2 or anti-CCL20 was reduced compared to the treated controls. However, these results were statistically significant only for FRCs, thus confirming the participation of FRCs in iDCs recruitment through CCR2/CCL2 and CCR6/CCL20 activation.

**DISCUSSION**

Stromal cells were first identified and characterized in murine LNs as structural cells (5, 26, 27). Recently, reports indicate that these cell populations are directly involved in the immune response initiation and regulation (16, 27). However, to our knowledge, there are only three recent articles that evaluated
the potential immune functions of stromal cells from human LNs (10, 28, 29). None of these studies performed extensive in vitro studies with different stimulation as we described in this manuscript.

In one of these studies (10), the authors isolated and compared human dermal fibroblasts with LN reticular fibroblastic cells gene expression after treatment with TNF-α, IL-4, IL-6, and IL-13. However, in their study, there was no distinction between FRCs and DNCs subsets. A second study compared the differences in gene expression between FRCs isolated from murine skin draining LNs and mesenteric LNs in steady state. However, they only described in detail the successful isolation and culture methods of human FRCs (28). The third study evaluated the role of stromal cells from tonsils and bone marrow on B cells derived from follicular lymphoma, but there was no distinction between FRCs and DNCs subsets (29). In contrast, our study characterized plastic adherent cells derived from human LNs as stromal cells according to their phenotype and their ability to differentiate in three mesodermal lineage cells and we distinguished FRCs and DNCs among adherent cells based on gp38/PDPN and CD31 expression.

Literature reports show that murine FRCs and DNCs respond to inflammatory stimuli by expressing several molecules involved in the immune response (9–12). We chose to use IFN-γ and TNF-α + IL-1β as inflammatory stimuli based on their specific but also diverse mechanisms of inducing immune cell response (17, 18, 30).

Our results show that upon stimulation with either IFN-γ or TNF-α + IL-1β, the population of DNCs and FRCs derived from human LNs upregulated chemokines gene expression and protein levels. However, there were differences between treatments and cell subpopulation. For instance, CCL2 and CCL20 secretion was significantly increased in FRCs in response to TNF-α + IL-1β stimulation when compared to IFN-γ treatment, untreated

**FIGURE 5 | Continued**
controls or similarly treated DNCs, corroborating the higher gene upregulation in FRCs compared to DNCs.

CCL2, also known as monocyte chemoattractant protein-1, is involved in chemotaxis of CCR2-expressing memory T cells, monocytes, and DCs to sites of inflammation produced by either tissue injury or infection. CCL20 also known as macrophage inflammatory protein-3α (MIP-3α) is implicated in lymphoid tissue function by recruiting either lymphocytes or dendritic cells through CCR6. Our findings corroborate a previous report by Vega et al., which also described an enhancement of CCL2 gene expression in human TNF-α-treated FRCs (10). In contrast, Malhotra et al. reported unaltered expression of CCL2 or CCL20 in mice-derived FRCs and DNCs after LPS in vivo stimulation (8).

We observed a more intense migration of monocyte-derived DCs toward TNF-α + IL-1β-treated FRCs. Monocyte-derived DCs expressed CCR2, CCR5, and CCR6 receptors, which are counterparts of CCL2, CCL5, CCL13, and CCL20, genes that were upregulated in treated FRCs. Despite the fact that around 90% of iDCs expressed CCR2 and only around 25% expressed CCR6, both receptors seem to play a role in recruiting iDCs since the independent neutralization of CCL2 or CCL20, their respective ligands, reduced migration toward TNF-α + IL-1β-treated FRCs. There are reports showing that CCR6 varies between individuals and that monocyte-derived iDCs expressing CCR6 are responsive to CCL20 (31, 32). This result confirmed the participation of FRCs in iDCs recruitment through the axis CCR2/CCL2 and CCR6/CCL20. In agreement, a report that correlates chemokines and DCs in sites of oral inflammation, verified that the expression of CCL2 and CCL20 was positively correlated with increased densities of immature CD1a (+) dendritic cells (33). In agreement with our observations, a study using monocyte-derived macrophages also demonstrated a role of the CCR2/CCL2 axis in the migration of these cells (34). The study further demonstrates a role for CCL2 in other leukocytes functions besides chemotaxis (34).

Studies using murine models reported CCL19 secretion by freshly isolated FRCs, both at resting state and after inflammatory stimuli (8, 12), as well as low levels of CCL19 and CXCL12 transcripts from cultured FRCs (35). In contrast, our results did not detect altered gene expression of CCL19 or CCL21, and we were not able to detect secretion of CCL19 by resting human FRCs and DNCs or following inflammatory stimuli. Our results are in agreement with Vega et al., who, after TNF treatment, did not detect gene expression of CCL19 or CCL21 by FRCs (10).

CXCL12 via CXCR4 is involved in naïve T cell and DCs entry in the LN (14). Our results showed a high expression of CXCR4 in LN-derived lymphocytes. We also showed that CXCL12 secretion was present in FRCs and DNCs cultures. However, CXCL12

**FIGURE 5 | Chemokine receptors on monocytes from peripheral blood and monocyte-derived DCs.** (A) Monocytes were isolated by positive selection (CD14) and cultured for 7 days with IL-4 (20 ng/mL) and GM-CSF (50 ng/mL) to differentiate into, (B) immature and, (C) mature dendritic cells when stimulated with LPS (100 ng/mL); each cellular subset was evaluated for CCR2, CCR3, CCR5, CCR6, CCR7, and CXCR4 expression by flow cytometry and the frequency of positive cells to chemokine receptors was plotted in the corresponding graphs to (D) monocytes, (E) immature and, (F) mature dendritic cells. Results are expressed in percentage and median of fluorescence intensity (MFI). Peripheral blood was collected from four healthy individuals for this assay.
secretion was not altered following inflammatory stimuli, corroborating previous reports (8, 36).

Literature reports that FRCs can secrete interleukins (5, 10). Indeed, FRCs, but also DNCs, stimulated with IFN-γ or TNF-α + IL-1β presented altered cytokine expression. Differences in the expression patterns were observed. For instance, FRCs and DNCs treated with TNF-α + IL-1β upregulated IL-6 gene expression, while IL-6-enhanced secretion was only significant for DNCs. In contrast, after IFN-γ treatment, there was IL-6 gene expression upregulation in DNCs but no significant alteration in protein secretion. A previous study described the upregulation of IL-6 transcripts in FRCs after TNF-α treatment (10). IL-6 is a cytokine that plays a role on CD4 T lymphocyte differentiation favoring a Th17 profile (37). FRCs and DNCs treated with TNF-α + IL-1β also displayed a clear upregulation of IL-8 (CXCL8) gene expression and protein secretion. However, IL-8 was overexpressed in FRCs after IFN-γ treatment, while IL-8 protein secretion remained unaltered (14). Corroborating our findings, a lymphoma study also reported upregulation of IL-8 in FRCs after TNF-α treatment (10). IL-8 plays a role as neutrophils chemoattractant, but since there are no neutrophils in LNs, this chemokine could be related to T cells in this microenvironment. Hess et al. reported an unexpected finding of CXCR1 (IL-8 receptor) on a CD8 T cell subset with high cytotoxic potential and terminally differentiated (38).

IL-11 was upregulated only in DNCs following TNF-α + IL-1β treatment, while IL-7R was upregulated only in FRCs. IL-7R expression has been described in stromal cells of secondary lymphoid organs and studies reported that IL-7 signaling through IL-7R modulates IL-7 production, consequently playing a role on T cell homeostasis (15, 39). We also observed low levels of IL-7 gene expression (Tables S1–S4 in Supplementary Material) and secretion by FRCs, which were enhanced after treatment with IFN-γ or TNF-α + IL-1β.

IL-10 is an anti-inflammatory cytokine that participates of Th1, NK cells, and macrophages inhibition during infection (40). Like other studies, we did not detect IL-10 expression or secretion by DNCs or FCRs under steady state or after inflammatory stimuli (6, 8, 26). However, IFN-γ treatment enhanced IL-18 binding protein (IL-18BP) in FRCs. IL-18BP is synthetized mainly by mononuclear cells and binds to IL-18 impairing their ligation with the receptor, downregulating the Th1 profile (41). IL-4-induced gene 1 (IL4I1) is only upregulated in DNCs by both

![Figure 6](image-url)
treatments and contributed to T cell receptor unresponsiveness in human T helper 17 cells (42).

Most chemokines and cytokines upregulated in FRCs and DNCs after IFN-γ or TNF-α + IL-1β stimuli may be described as pro-inflammatory, and few have been described as hemostatic or with dual function (43). This result suggests that these cells respond accordingly to the inflammatory stimulus received and that they participate of the immune response by recruiting and
stimulating immune cells after initial signals of inflammation/infection.

The diversity of interleukins and chemokines secreted by FRCs and DNCs indicate specific signaling and recruitment of these lymphocytes subsets and DCs. This effect should depend on the inflammatory environment. Taken together, our results suggest that DNCs and FRCs play an important role in the recruitment of immune cells to secondary lymphoid organs, including DC and T cells migration. Further, we have confirmed an important participation of FRCs in DCs recruitment through the axis CCR2/CCL2 and CCR6/CCL20.

**AUTHOR CONTRIBUTIONS**

Performed the experiments: LM, DCP, DP, HA, CA, PS, MA, TA, and FR. Analyzed the data: LM, PS, DCP, and FR. Contributed with patient samples: AM, AC, SB, PS, and LR. Contributed reagents/materials/analysis tools: LM. Conceived and designed the experiments: LM. Contributed to the writing and revising the manuscript: LM and PS.

**ACKNOWLEDGMENTS**

We thank Dr. Carla Piccinato for the help with the confocal microscopy experiments, José Belém de Oliveira Neto for proof-reading, and Sociedade Beneficente Israelita Brasileira Hospital Albert Einstein (SBIBHAE) for all the support received.

**FUNDING**

This work was financed by FAPESP grant number 2014/15504-7.

**SUPPLEMENTARY MATERIAL**

The Supplementary Material for this article can be found online at http://journal.frontiersin.org/article/10.3389/fimmu.2017.00141/full#supplementary-material.

**FIGURE S1 | Double-negative cell (DNC) and fibroblastic reticular cell (FRC) sorting purity.** (A) Stromal cells isolated from lymph nodes were sorted in two populations. (B,C) DNCs and. (D–F) FRCs according to gp38/PDPN expression. After DNCs and FRCs expansion in culture and before each experiment, gp38/PDPN expression was verified, and when purity was lower than 95%, (E,F) cells were resorted.

**FIGURE S2 | Gate strategy for monocytes, dendritic cells, and lymphocytes.** (A) Monocytes were gated on FSC vs CD14, followed by CD14 vs CD33, and the double-positive cells were analyzed for CD80, CD86, CD209, and HLA-DR. (B) Immature and, (C) mature dendritic cells were gated on FSC vs CD14, followed by CD14 vs CD33, and the CD14-CD33 positive cells were analyzed for CD80, CD86, CD209, and HLA-DR. (D) Lymphocytes were gated on flow cytometry v.3D, and the CD3 cells were sorted for CD4 and CD8, and CD3, CD3CD4, or CD3CD8 positive cells were analyzed for chemokine receptors, expression here illustrated by CCR6.

**FIGURE S3 | Histopathology of human lymph nodes (LNs).** (A) LN derived from larynx cancer patient LN04, (B) LNs derived from liver donor LN16, (C) LN derived from diverticulitis LN12 hematoxylin–eosin (HE) immunostaining show the organ integrity LN immunohistochemistry for CD3, CD20, or CD68 show the presence of T lymphocytes (CD3), B lymphocytes (CD20), and macrophages (CD68), respectively (magnification of 10x).
REFERENCES

1. Von Andrian UH, Mempel TR. Homing and cellular traffic in lymph nodes. Nat Rev Immunol (2003) 3(11):867–78. doi:10.1038/nri1222

2. Turley SJ, Fletcher AL, Elpek KG. The stromal and haematopoietic antigen-presenting cells that reside in secondary lymphoid organs. Nat Rev Immunol (2010) 10(12):813–25. doi:10.1038/nri2886

3. Acton SE, Astarita JL, Malhotra D, Lukacs-Kornek V, Franz B, Hess PR, et al. Podoplanin-rich stromal networks induce dendritic cell motility via activation of the C-type lectin receptor CLEC-2. Immunity (2012) 37(2):276–89. doi:10.1016/j.immuni.2012.05.022

4. Sobocinski GP, Toy K, Bobrowski WF, Shaw S, Anderson AO, Kaldjian EP. Ultrastructural localization of extracellular matrix proteins of the lymph node cortex: evidence supporting the reticular network as a pathway for lymphocyte migration. BMC Immunol (2010) 11:42. doi:10.1186/1471-2472-11-42

5. Link A, Vogt TK, Favre S, Britschgi MR, Acha-Orbea H, Hinz R, et al. Fibroblastic reticular cells in lymph nodes regulate the homeostasis of naive T cells. Nat Immunol (2007) 8(11):1255–65. doi:10.1038/ni1513

6. Fletcher AL, Lukacs-Kornek V, Reynoso ED, Pinner SE, Bellemare-Pelletier A, Curry MS, et al. Lymph node fibroblastic reticular cells directly present peripheral tissue antigen under steady-state and inflammatory conditions. J Exp Med (2010) 207(4):689–97. doi:10.1084/jem.20092642

7. Cohen JN, Guidi CJ, Tewalt EF, Qiao H, Rouhani SJ, Ruddell A, et al. Lymph node resident lymphatic endothelial cells mediate peripheral tolerance via Aire-independent direct antigen presentation. J Exp Med (2010) 207(4):681–8. doi:10.1084/jem.20092465

8. Malhotra D, Fletcher AL, Astarita J, Lukacs-Kornek V, Tayailia P, Gonzalez SE, et al. Immunological Genome Project Consortium. Transcriptional profiling of stroma from inflamed and resting lymph nodes defines immunological hallmarks. Nat Immunol (2012) 13(5):499–510. doi:10.1038/ni.2262

9. Katakai T, Hara T, Sugai M, Gonda H, Shimizu A. Lymph node fibroblastic reticular cells construct the stromal reticulum via contact with lymphocytes. J Exp Med (2004) 200(6):783–95. doi:10.1084/jem.20040254

10. Vega F, Coombee KR, Thomazy VA, Patel K, Lang W, Jones D. Tissue specific function of lymph node fibroblastic reticulum cells. Pathobiology (2006) 73(2):71–81. doi:10.1159/000094949

11. Siegert S, Luther SA. Positive and negative regulation of T cell responses by fibroblastic reticular cells within paracortical regions of lymph nodes. Front Immunol (2012) 3:285. doi:10.3389/fimmu.2012.00285

12. Yang CY, Vogt TK, Favre S, Scarpellino L, Huang HY, Zacchini-Cottier F, et al. Trapping of naive lymphocytes triggers rapid growth and remodeling of the fibroblast network in reactive murine lymph nodes. Proc Natl Acad Sci U S A (2013) 111(1):E109–18. doi:10.1073/pnas.1215285111

13. Chao IF, Ransohoff RM. The many roles of chemokines and chemokine receptors in inflammation. N Engl J Med (2006) 354(6):610–21. doi:10.1056/NEJMra052723

14. Griffith JW, Sokol CL, Luster AD. Chemokines and chemokine receptors: positioning cells for host defense and immunity. Annu Rev Immunol (2014) 32:659–702. doi:10.1146/annurev-immunol-032713-120145

15. Guimond M, Veenstra RG, Grindler DJ, Zhang H, Cui Y, Murphy RD, et al. Defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy (2006) 8(4):315–7. doi:10.1080/14653240600855905

16. Normanton M, Alvarenga H, Hamerschlag N, Ribeiro A, Kondo A, Rizzo LV, et al. Interleukin 7 plays a role in T lymphocyte apoptosis inhibition driven by mesenchymal stem cell without favoring proliferation and cytokines secretion. PLoS One (2014) 9(9):e106673. doi:10.1371/journal.pone.0106673

17. Eckwall AK, Eisler T, Anderberg C, Jin C, Karlsson N, Brisslert M, et al. The tumour-associated glycoprotein podoplanin is expressed in fibroblast-like synovocytes of the hyperplastic synovial lining layer in rheumatoid arthritis. Arthritis Res Ther (2011) 13(2):R40. doi:10.1186/ar3274

18. Homma M, Minami-Hori M, Takahashi H, Iizuka H. Podoplanin expression in wound and hyperproliferative psoriatic epidermis: regulation by TGFB-β and STAT-3 activating cytokines, IFN-γ, IL-6, and IL-22. J Dermatol Sci (2012) 65(2):134–40. doi:10.1016/j.jdermsci.2011.11.011

19. Ofer M. Trans-well migration assay. Protoc Exch (2006). doi:10.1038/nprot.2006.210

20. Meier-Ruge WA, Bruder E. Current concepts of enzyme histochemistry in modern pathology. Pathobiology (2008) 75(4):233–43. doi:10.1159/000132384

21. Guilliams M, Ginhoux F, Jakubzick C, Naik SH, Onai N, Schraml BU, et al. Dendritic cells, monocytes and macrophages: a unified nomenclature based on ontogeny. Nat Rev Immunol (2014) 14(8):571–8. doi:10.1038/nri3712

22. Lukacs-Kornek V, Malhotra D, Fletcher AL, Acton SE, Elpek KG, Tayailia P, et al. Regulated release of nitric oxide by nonhematopoietic stroma controls expansion of the activated T cell pool in lymph nodes. Nat Immunol (2011) 12(11):1096–104. doi:10.1038/ni.2112

23. Fletcher AL, Acton SE, Knoblich K. Lymph node fibroblastic reticular cells in health and disease. Nat Rev Immunol (2015) 15(6):350–6. doi:10.1038/nri3846

24. Fletcher AL, Malhotra D, Acton SE, Lukacs-Kornek V, Bellemare-Pelletier A, Curry M, et al. Reproducible isolation of lymph node stromal cells reveals site-dependent differences in fibroblastic reticular cells. Front Immunol (2011) 2:35. doi:10.3389/fimmu.2011.00035

25. Amé-Thomas P, Maby-El Hajami H, Monvoisin C, Jean R, Monnier D, Cautel-Maugendre S, et al. Human mesenchymal stem cells isolated from bone marrow and lymphoid organs support tumor B-cell growth: role of stromal cells in follicular lymphoma pathogenesis. Blood (2007) 109(2):693–702. doi:10.1182/blood-2006-05-020800

26. Saperstein S, Chen L, Oaks D, Pryhuber G, Finkelstein J. IL-1-beta augments TNF-alpha-mediated inflammatory responses from lung epithelial cells. J Interferon Cytokine Res (2009) 29(5):273–84. doi:10.1089/jir.2008.0076

27. Dieu MC, Vanbervliet B, Vicari A, Bridon JM, Oldham E, Ait-Yahia S, et al. Selective recruitment of immature and mature dendritic cells by distinct chemokines expressed in different anatomic sites. J Exp Med (1998) 188(2):373–86. doi:10.1084/jem.188.2.373

28. Cirone M, Conte V, Farina A, Valia S, Trivedi P, Granato M, et al. HHV-8 mal cells in follicular lymphoma pathogenesis. PLoS One (2014) 9(9):e107110. doi:10.1371/journal.pone.0107110

29. Bonton S, Scheller J, Chalaris A, Schmidt-Arras D, Rose-John S. The pro- and anti-inflammatory properties of the cytokine interleukin-6. Biochim Biophys Acta (2011) 1813(5):878–88. doi:10.1016/j.jbmb.2011.01.034

Frontiers in Immunology | www.frontiersin.org 16 February 2017 Volume 8 Article 141
38. Hess C, Means TK, Autissier P, Woodberry T, Altfield M, Addo MM, et al. IL-8 responsiveness defines a subset of CD8 T cells poised to kill. Blood (2004) 104(12):3463–71. doi:10.1182/blood-2004-03-1667

39. Onder L, Narang P, Scandella E, Chai Q, Iolyeva M, Hoorweg K, et al. IL-7-producing stromal cells are critical for lymph node remodeling. Blood (2012) 120(24):4675–83. doi:10.1182/blood-2012-03-416859

40. Couper KN, Blount DG, Riley EM. IL-10: the master regulator of immunity to infection. J Immunol (2008) 180(9):5771–7. doi:10.4049/jimmunol.180.9.5771

41. Dinarello CA, Novick D, Kim S, Kaplanski G. Interleukin-18 and IL-18 binding protein. Front Immunol (2013) 4:289. doi:10.3389/fimmu.2013.00289

42. Santarlasci V, Maggi L, Mazzoni A, Capone M, Querci V, Rossi MC, et al. IL-4-induced gene 1 maintains high Tob1 expression that contributes to TCR unresponsiveness in human T helper 17 cells. Eur J Immunol (2014) 44(3):654–61. doi:10.1002/eji.201344047

43. Palomino DC, Marti LC. Chemokines and immunity. Einstein (Sao Paulo) (2015) 13(3):469–73. doi:10.1590/S1679-450820155003438

Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2017 Severino, Palomino, Alvarenga, Almeida, Pasqualim, Cury, Salvalaggio, De Vasconcelos Macedo, Andrade, Aloia, Bromberg, Rizzo, Rocha and Marti. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.